Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREX-SASS study of brexpiprazole for social anxiety symptoms in schizophrenia
jRCTs031200258Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of brexpiprazole in schizophrenia and schizoaffective disorder, sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline in LSAS-J at Week 12 after initiation of brexpiprazole, excluding use of restricted concomitant medications. Started Aug 2021; status: completed.
02
Drugs
brexpiprazole
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on jRCTs031200258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200258.